The assay is a cell-based technique that uses time-resolved fluorescence resonance energy transfer (TR-FRET) to measure cytosolic IP1 levels in cell lysates. The goal is to identify new cell-permeable inhibitors of inositol monophosphatase (IMPase), which catalyzes the hydrolysis of inositol-1-phosphate (IP1) and plays a role in the synthesis of phosphatidylinositol. Lithium is used in small amounts to potentiate the response of weak activators. The successful development of a cell-permeable IMPase inhibitor could lead to an alternative therapy for bipolar disorder with reduced side effects compared to lithium. Is the molecule effective to this assay?